Diverse Pipeline of Candidates Identified

Program

Discovery

Proof of Principle

Lead Optimisation

Pre-Clinical

Phase I

BVX001

Bispecific ADC

Indication: AML

Targets: CD33 x CD7

Multiple Candidates

Bispecific ADCs

Indication: Haem & solid tumour indications

Targets: Undisclosed